Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides

Yanmei Li1,2
Ruqing Su3
Shuqin Xu2
Qingjun Huang1
Haiyun Xu1,2

1The Mental Health Center, Shantou University Medical College, Shantou, Guangdong Province, People’s Republic of China; 2Department of Anatomy, Shantou University Medical College, Shantou, Guangdong Province, People’s Republic of China; 3Department of Forensics and Pathology, Shantou University Medical College, Shantou, Guangdong Province, People’s Republic of China

Abstract: Clozapine is an atypical antipsychotic with therapeutic efficacy in treatment-resistant schizophrenia patients and low incidence of extrapyramidal side effects. However, the use of clozapine has been limited by its adverse effects on metabolism. Artesunate is a semisynthetic derivative of artesiminin and was shown to decrease the plasma cholesterol and triglyceride in rabbits and rats in recent studies. The aim of this study was to examine possible effects of artemisinin on the clozapine-induced metabolic alterations in rats given saline, clozapine, artemisun, or clozapine plus artemisun for 6 weeks. The clozapine group showed significantly high plasma levels of triglyceride, hepatic steatosis, and fibrosis along with high levels of C-reactive protein, alanine aminotransferase, and aspartate aminotransferase compared to the saline group. But the treatment had no effect on weight gain and caused no hyperglycemia, hyperinsulinemia, and behavioral changes in the rats. More significantly, these clozapine-induced changes were not seen in rats coadministered with clozapine plus artemisun. These results added evidence supporting psychiatrists to try add-on treatment of artemisinin in schizophrenia patients to ameliorate clozapine-induced adverse metabolic effects.

Keywords: artemisun, clozapine, dyslipidemia, hepatic steatosis, schizophrenia

Introduction

Clozapine is an atypical antipsychotic distinguished from other antipsychotics by its efficacy in some treatment-resistant patients and its low incidence of extrapyramidal side effects.1–3 However, the use of clozapine has been limited by its adverse effects on metabolism in schizophrenia patients, in addition to a risk of agranulocytosis.4 The adverse metabolic effects associated with clozapine administration include weight gain,5,6 glucose intolerance,5,7,8 visceral obesity,9 hypertension,10 and dyslipidemia.7,11–15 These metabolic syndromes may contribute to the increased cardiovascular mortality in schizophrenia patients. Indeed, a recent clinical cohort study with 355 clozapine-using patients reported that older age of commencement with clozapine was associated with increased risk of cardiovascular abnormalities and that an increase in body mass index (BMI) was consistently and significantly associated with all metabolic events.16 Moreover, neuroleptic malignant syndrome (NMS) has been a medical emergency in the emergency department, which is associated with the use of antipsychotic drugs, such as typical and atypical antipsychotics including clozapine.17 Although it has been generally regarded as an idiosyncratic drug reaction, implying that it is unpredictable and dose-independent, NMS can be described as a complex cascade of dysregulation in multiple neurochemical and neuroendocrine systems, potentially culminating in an...
end-stage hypermetabolic syndrome. Therefore, research efforts aiming at mitigating these clozapine-induced metabolic disturbances are of paramount importance.

Artesunate is a semisynthetic derivative of artemisinin isolated from the traditional Chinese medicine Artemisia annua L. Like artemisinin, which exhibits a wide variety of efficacy such as immunosuppressive, anti-inflammatory, antitumor, antiangiogenic, and antiparasitic actions, artesunate showed anti-inflammatory properties in vitro and in vivo models of rheumatoid arthritis. In a recent study, we found that artesunate decreased expression of the proinflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and IL-17α in a rat model of collagen-induced arthritis. In a more recent study, artemesunate attenuated the multiple organ injury and dysfunction of rats submitted to hemorrhage shock, by activating the well-known Akt-survival pathway. The activation of Akt may result in phosphorylation, and activation of eNOS, thus, enhances the formation of NO, which is pivotal for the preservation of microvascular perfusion, reducing organ injury. In addition, Akt may turn off the catalytic activity of GSK-3β, which in turn reduces inflammation.

In addition to its anti-inflammatory properties, artesunate was shown to significantly decrease the plasma cholesterol and triglyceride in rabbits. Furthermore, this drug attenuated liver steatosis and reduced the area of aortic root lesions in the rabbit. This hypolipidemic effect of artesunate was confirmed in a recent animal study, in which the effects of artesunate on hyperlipidemia were determined in rats fed a Western-type diet that developed a hyperlipidemia. Artesunate alone, or in combination with ursolic acid, prevented hyperlipidemia. Ursolic acid or artesunate alone significantly decreased the plasma triglyceride, but had no effect on the levels of cholesterol. The combination of them, however, reduced both triglyceride and cholesterol, and the effects were more potent than either agent alone. In line with the above in vivo findings, artesunate inhibited lipid accumulation and triglyceride synthesis without inducing cell toxicity during 3T3-L1 adipocytes differentiation of 8 days and human primary adipocytes differentiation of 20 days.

On the basis of the above literature review, it is rational to hypothesize that artesunate may prevent or mitigate the clozapine-induced metabolic alterations in subjects. To test this hypothesis, this study was performed with adult male Wistar rats treated with clozapine and/or artesunate for 6 weeks. Chronic administration of clozapine was found to increase plasma triglyceride and lead to hepatic steatosis and cirrhosis in the rats. Significantly, these clozapine-induced adverse metabolic effects were not seen in rats coadministered with clozapine and artesunate during the same period.

**Materials and methods**

**Drugs**

Clozapine and artesunate were purchased from Sigma-Aldrich (St Louis, MO, USA). Clozapine was first dissolved in glacial acetic acid, then diluted to its final concentration (2.0 mg/mL) with sterilized saline, and the pH value was buffered to 6.0 with sodium hydroxide. Artesunate stock solution was prepared by dissolving it in 5% sodium bicarbonate, followed by the addition of distilled water. Then the stock solution was stored at 4°C until use. The final concentration of artesunate work solution was 0.6 mg/mL and pH = 6.0 adjusted with glacial acetic acid. The drug solutions were freshly prepared every 2 days.

**Animals and drug treatments**

A total of 37 adult male Wistar rats were used in this study. The rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). They were housed in groups in the Shantou University Medical College animal facility with free access to food and water and a 12 h dark/12 h light cycle, at a constant temperature of 24°C±1°C and a relative humidity of 60%. All animal procedures applied in this study were in accordance with the guidelines set up by the Animal Care and Use Committee of Shantou University Medical College; the study was approved by the committee.

After acclimation for 7 days, the rats were divided into four groups. In the vehicle control group (termed as saline group; n=8), rats were given (intraperitoneal [i.p.]) sterilized saline (pH was adjusted to 6.0; 0.5 mL/100 g) once a day for 6 weeks. In the clozapine group (n=10), rats were given the same volume of clozapine solution (pH = 6.0; 10 mg/kg, i.p.) once a day during the same period. In the artesunate group (n=10), rats were given artesunate solution (pH = 6.0; 3 mg/kg, i.p.) once a day during the same period. In the clozapine + artesunate group (n=9), rats were given clozapine (10 mg/kg, i.p.) and artesunate (3 mg/kg, i.p.) in the order with a 2-h interval to minimize the possible effect of this larger volume of injection, which was the double of that injected for the other three groups, on the rats. During the experimental period the rats were weighed every week. The doses of artesunate and clozapine used in this study were based on the results of the primary experiment of this study and of our previous studies.

**Behavioral tests**

Twenty-four hours after the last injection, the elevated plus maze, Y-maze, and social interaction tests were performed.
with rats in the order in an interval of 24 h to evaluate the possible effects of clozapine and artesunate on rats’ anxiety level, spatial working memory, and social interaction as described previously. For elevated plus maze test, a rat was placed at the central junction of the four arms while facing an open arm and allowed to move freely in the maze for 5 min during which period the activity of the rat was recorded. Decreases in time spending on open arms and increases in closed arms were used as a measure of anxiety-like behavior. For Y-maze test, each rat was placed at the end of one arm of a symmetrical Y-maze and allowed to move freely through the maze during an 8-min test period. The total number and series of arm entries were recorded. The number of overlapping entrance sequences (eg, ABC, BCA) defines the number of spontaneous alternation. For social interaction test, individual rat was introduced into an open-field (100×100 cm) and its moving trajectory was tracked for two consecutive sessions of 150 s. During the first session, an empty wire mesh cage (12×12×18 cm) was placed at one end of the open field. During the second session, the conditions were identical except that a social target animal (an unfamiliar rat of the same gender [male]) had been introduced into the cage. Between the two test sessions, the tested rat was removed from the arena and placed back to its home cage for ~60 s. The video-tracking data from both the no-target and target conditions were used to determine the time spent by the tested rat in the interaction zone (a 16-cm-wide corridor surrounding the cage) and the corners of the open field opposite to the location of the cage using a video tracking program (Noldus Information Technology, Wageningen, the Netherlands).

Biochemical analyses

For blood sugar test, rats were fasted for 12 h and blood samples were collected from the tail veins of them. The blood glucose was measured with a blood glucometer (XGP8538TT, Johnson; Shanghai, China). For the measure-ment of other indices including plasma triglyceride, total cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), the rats were deeply anesthetized by sodium pentobarbital (40 mg/kg) and blood was taken by intracardiac puncture and collected in tubes containing 10% ethylenediaminetetraacetic acid solution. Then the blood sample was centrifuged at 4°C (1,700 rpm) for 10 min to separate blood cells from plasma, which was kept at −20°C until analysis. The measurement of ALT, AST, triglyceride, and total cholesterol levels was performed using the assay kits from Nanjing Jiancheng Biological Engineering Institute (Nanjing, China) and following the instructions provided by the manufacturer. The final values were read by Tecan Microplate Reader (Infinite M200 Pro, Tecan Trading AG, Männedorf, Switzerland).

Enzyme-linked immunosorbent assay

Insulin, IL-1β, TNF-α, and C-reactive protein (CRP) of plasma were analyzed by means of enzyme-linked immuno-sorbent assay method using the assay kit from Mercodia AB (Uppsala, Sweden) for insulin and kits from Boster (Wuhan, China) for the others. At the end, the plates were read by the microplate reader (Bio-Rad laboratories, Inc., CA, USA) at 450 nm.

Histopathological examination

Under a deep anesthetization, liver tissue samples of rats were collected and kept in 10% formalin solution for 3 days. Then the tissue samples were embedded with paraffin, followed by sectioning (4 μm) with a Leica microtome (RM2135; Leica, Heidelberg, Germany). The sections were stained by the hematoxylin–eosin (HE) method and examined under a Zeiss microscope (Zeiss Instruments Inc., Göttingen, Germany).

Immunohistochemical staining

Immunohistochemical staining was performed using the primary antibody against α-smooth muscle actin (α-SMA) and an immunohistochemical assay kit (SV0001-mouse IgG) from Boster (Wuhan, China) to examine the activation of hepatic stellate cells and hepatic fibrosis/cirrhosis of rats. Liver specimens were fixed in 10% neutral buffered formalin and then embedded in paraffin. Liver tissue sections (4 μm) were deparaffinified by xylene and rehydrated in gradient ethanol solutions. After washing in distilled water for 5 min 3 times, the sections were incubated in 3% H₂O₂ for 10 min at 22°C to block the endogenous enzymes. Following washing in phosphate-buffered saline (PBS), the sections were incubated in the 1.2% sodium citrate solution under 22°C for 45 min. After washing 3×5 min in PBS, the sections were incubated in 5% bovine serum albumin at 22°C for 10 min, followed by incubation with the primary antibody to α-SMA (1:100) overnight at 4°C and the following incubation at 22°C for 45 min. After washing with PBS (3×5 min), the sections were incubated with the goat anti-mouse immunoglobulin G–horseradish peroxidase working solution at 37°C for 30 min. After washing 3×5 min in PBS, the immunohistochemical complex was visualized with diaminobenzidine solution at 22°C for 8 min. After stopping the reaction and washing in distilled water, the sections were counterstained with hematoxylin, followed by differentiation.
in 1% hydrochloric alcohol for 3 s. The immunohistochemical controls were performed as above, but with the omission of the primary antibody. Finally, the immunohistochemically stained sections were examined under a Zeiss microscope of Axio Imager A2 (Zeiss instruments Inc.). No positive immunostaining was found in any of the control sections.

**Statistical analysis**

All data were expressed as means ± standard error of the mean and analyzed with the software GraphPad Prism (version 5.01). By considering clozapine and artesunate treatments as two main factors, two-way analysis of variance (ANOVA) was performed followed by one-way ANOVA along with Bonferroni post-tests for all data sets. For body weight of each group, one-way ANOVA was performed followed by Bonferroni post hoc tests, in addition to two-way ANOVA performed for the data of each indicated time point. When a p-value was <0.05, the difference/effect was considered significant.

**Results**

**Effects of clozapine and artesunate on behaviors of rats**

In the Y-maze, rats in all four groups (in the order of saline, clozapine, artesunate, and clozapine + Artesunate groups) performed similarly with comparable frequencies of arm visiting (12±2, 11±1, 11±1, and 14±2, respectively) and spontaneous alternations (65.30%±1.38%, 69.87%±4.91%, 66.50%±4.02%, and 66.42%±4.99%, respectively). Two-way ANOVA revealed no interaction between clozapine and artesunate \( (F_{1,33}^{}=1.63, p=ns) \) for arm visiting frequency; \( F_{1,33}^{}=1.23, p=ns \), for spontaneous alternation). Similarly, no differences were found among the four groups in terms of their performances in the elevated plus maze and social interaction tests (not shown).

**Artesunate and clozapine showed no effects on the body weight and levels of blood sugar and insulin of rats**

Over the 6-week experimental period, rats in all four groups showed similar weight gain. Even for week 6, two-way ANOVA indicated no interaction between artesunate and clozapine \( (F_{1,33}^{}=0.86, p=ns) \) on the body weight of rats. One-way ANOVA showed that both clozapine \( (F_{1,33}^{}=2.63, p=ns) \) and artesunate \( (F_{1,33}^{}=0.07, p=ns) \) administrations had no significant effect on the body weight of rats (Figure 1). However, post hoc comparisons revealed significant differences between the groups Artesunate and Clozapine + Artesunate at the time points of weeks 5 and 6. Two-way ANOVA also indicated no interaction between artesunate and clozapine treatments in terms of the blood sugar \( (F_{1,33}^{}=1.22, p=ns) \) and insulin \( (F_{1,33}^{}=0.77, p=ns) \) levels. Bonferroni post-tests showed no significant differences between any two groups with respect to blood sugar \( (4.1±0.1, 3.7±0.2, 3.8±0.2, \text{ and } 3.8±0.2 \text{ mM/L, respectively}) \) and insulin \( (1.732±0.093, 1.510±0.285, 1.118±0.271, \text{ and } 1.318±0.191 \mu\text{g/L, respectively)} \) levels of rats.

**Effects of clozapine and artesunate on plasma triglyceride and total cholesterol**

For plasma triglyceride levels of rats, two-way ANOVA indicated no interaction between artesunate and clozapine \( (F_{1,33}^{}=0.42, p=ns) \). One-way ANOVA revealed a significant effect of clozapine \( (F_{1,33}^{}=16.14, p<0.001) \), but the effect of artesunate was marginal \( (F_{1,33}^{}=2.86, p=0.1) \). Bonferroni post-tests showed that clozapine significantly increased levels of plasma triglyceride compared to the saline group \( (0.9997±0.083 \text{ mM/L vs } 0.685±0.0698 \text{ mM/L, } p<0.01) \). But this clozapine-induced increase was not seen in the other two groups (Figure 2A). Interestingly, all four groups showed comparable levels of total cholesterol as shown in Figure 2B.

**Artesunate prevents rats from the clozapine-induced hepatic steatosis and fibrosis along with functional impairment**

On the HE-stained tissue sections from all rats \( (n=4–5/\text{group}) \), the lobular organization of liver is evident under the
microscope, characterized with hepatic cords separated by vascular sinusoids connected to the central vein of the liver as shown in Figure 3. However, the typical architecture of hepatic lobules was damaged in liver samples from four of the five rats in the clozapine group; within some of hepatocytes in these rats were empty holes (or vacuoles) where the lipid had been cleared (Figure 3B). No pathological changes were found in liver samples from the other three groups.

The immunohistochemical staining showed evident α-SMA immunoreactivity in liver samples from three of the five rats in the clozapine group. The α-SMA-positive cells appeared among hepatocytes; they even outnumbered hepatocytes and converged to form a large focus of fibrosis in the liver. However, these clozapine-induced pathological observations were not seen in the liver tissue of the other three groups, where α-SMA immunoreactivity was seen only in the wall of blood vessels (Figure 4).

Along with the hepatic steatosis and fibrosis, clozapine-treated rats also showed higher levels of ALT and AST, compared to saline group. Two-way ANOVA indicated a significant interaction between clozapine and artesunate on plasma levels of ALT of rats ($F_{1,33} = 7.62$, $p<0.001$).
One-way ANOVA showed that both clozapine ($F_{(1,33)}=5.82, p<0.05$) and artesunate ($F_{(1,33)}=4.74, p<0.05$) showed significant effects. Bonferroni post-tests showed that Clozapine significantly increased levels of ALT in rats compared to the saline group (46.02±5.41 IU/L vs 27.67±2.72 IU, $p<0.01$). But this clozapine-induced increase was not seen in the other two groups (Figure 5A). The same statistical conclusions also held true for the AST data of all the four animal groups (Figure 5B).

**Effects of clozapine and artesunate on circulating inflammation markers in rats**

Regarding circulating levels of CRP in rats, two-way ANOVA indicated no interaction between artesunate and clozapine ($F_{(1,33)}=1.79, p=ns$). One-way ANOVA revealed a significant effect of clozapine ($F_{(1,33)}=6.85, p<0.05$), but the effect of artesunate did not reach significant level ($F_{(1,33)}=1.76, p=0.1$). Bonferroni post-tests showed that Clozapine significantly increased levels of plasma CRP compared to the saline group (83.11±10.27 pg/mL vs 40.07±4.60 pg/mL, $p<0.01$). But this clozapine-induced increase was not seen in the other two groups (Figure 6A). Interestingly, all four groups showed comparable levels of plasma IL-1β (Figure 6B) and TNF-α (Figure 6C).

**Discussion**

As summarized in a recent systematic review and meta-analysis, metabolic alteration risk was significantly higher with clozapine, followed by olanzapine. The most prevalent manifestations of metabolic alterations in clozapine- and olanzapine-treated patients were weight gain, hypertriglyceridemia, and insulin resistance. In addition, hepatic steatosis was among the most prevalent risk factors found in patients treated with atypical antipsychotics, especially for those naïve to treatment, in which the drugs caused a more noticeable increase in weight compared with
chronically treated patients. Some of these metabolic adverse effects were also mimicked in animal studies. For example, clozapine elevated serum lipid levels in Sprague-Dawley (S-D) rats, increased serum triacylglycerol, total cholesterol, free fatty acids, progesterone, and corticosterone levels in the S-D rats, led to hepatic accumulation of lipids in female S-D rats, and resulted in hyperglycemia, hyperinsulinemia, and insulin resistance in Wistar albino rats. In the present study, daily intraperitoneal injection of clozapine for 6 weeks significantly increased plasma levels of triglycerides, led to hepatic steatosis and fibrosis along with increased activities of ALT and AST in male Wistar rats, but showed no effects on blood glucose, insulin levels, and total cholesterol. Some of the clozapine-induced metabolic adverse effects such as increased plasma levels of triglycerides and hepatic steatosis were same as those reported by the above-mentioned previous animal studies, while the others including increased total cholesterol and hyperglycemia were not seen in the present study.

In comparing all the animal studies including the present one, we noticed some discrepancies across them. In the study by EI-Seweidy et al., clozapine was given orally at a dose of 10 mg/kg body weight daily for 6 weeks and the treatment paradigm resulted in hyperglycemia, hyperinsulinemia, and insulin resistance, whereas the drug was administered by intraperitoneal injection daily for 4 or 6 weeks in the other studies, including the present study and the two studies by Cai et al. and Dang et al., all of which showed alterations of dyslipidemia in the absence of changes in glucose metabolism. These discrepancies suggest that the delivery route is an important factor affecting the metabolic side effects of clozapine on subjects. The association of oral administration of clozapine and the concomitant derangement of glucose metabolism in the animal study by EI-Seweidy et al. helps us understand the insulin resistance and hyperglycemia induced by clozapine in schizophrenia patients who take the drugs orally.

One of the anthropometric measurements relevant to metabolic alterations induced by atypical antipsychotics is the weight gain in patients. As reviewed in the meta-analysis by Allison et al., human studies have consistently shown that clozapine and olanzapine are associated with the greatest weight gain. In a recent review, clozapine and olanzapine were identified as conferring the highest risk of weight gain among atypical antipsychotics, with quetiapine and risperidone having intermediate risk, and aripiprazole and ziprasidone having minimal risk. The meta-analyses in this review value for mean and 95% CI of weight change after antipsychotic treatments (up to 12 weeks). Contrary to results of human studies, most of the animal studies showed no weight gain after clozapine treatments, some of the studies even reported weight loss after clozapine treatment. However, most of the animal studies with olanzapine reported significant weight gain. This phenomenon seen in animal studies, plus the clinical observation that clozapine induces weight gain in some of schizophrenia patients, suggest that the weight gain in schizophrenia patients is more likely due to risk factors for schizophrenia, including genetic factors. For example, variant sites across the IL-1β gene, specifically rs16,944*GA, rs11,43,634*G, and rs48,49,127*A, were associated with greater antipsychotics-induced weight gain in schizophrenia patients. In addition, the indirect effects of drugs on patients, including inactive lifestyle, length of the disease, poor dietary choices, and smoking, may play an important role in the drugs-induced weight gain. In line with the second suggestion, olanzapine was shown to reduce locomotor activity of rats, and this action was significantly correlated with weight gain, suggesting that reduced activity partially contributed to the weight gain induced by olanzapine. In the present study, all animal groups displayed similar performances in the Y-maze, elevated plus maze, and social interaction tests, suggesting that each individual drug treatment and combination of clozapine and artesunate had no effect on behaviors of rats, which may explain in part why clozapine treatment paradigm caused no weight gain in this study.

There is a growing body of evidence supporting an important role of cytokine dysfunction in metabolic disturbances such as antipsychotics-induced weight gain in schizophrenia. Specifically, the effects of clozapine and olanzapine on weight gain may be closely related to their effects on cytokine networks as demonstrated in a study by Kluge et al. In that study, 30 patients diagnosed with schizophrenia, schizophréniform, or schizoaffective disorder were randomized to either clozapine or olanzapine treatment for 6 weeks. Data were longitudinally collected on BMI and plasma levels of leptin and cytokines including TNF-α, soluble TNF receptor (sTNFR)-1, sTNFR-2, IL-6, and sIL-2R. All cytokine levels were found to significantly change over time, with the exception of IL-6 and sTNFR-1 among olanzapine-treated patients. In addition, TNF-α, sTNFR-1, sTNFR-2, and sIL-2R levels correlated with BMI after 6 weeks of treatment. These anti-inflammatory effects of clozapine were also reported in recent basic studies. One of them showed that clozapine ameliorated the production of microglia-derived TNF-α following the addition of lipopolysaccharide, while the other one found...
that clozapine administration reversed microglial activation and inducible-nitric-oxide-synthase increase in Wistar rats administered the viral mimetic polyriboinosinic-polyribicytidilic acid (poly I:C). Considering all these previous studies, it is plausible to suggest that the absence of weight gain in clozapine-treated animals may be attributed, at least in part, to its anti-inflammatory action. In line with this suggestion, clozapine treatment paradigm in the present study did not increase plasma levels of cytokines (IL-1β and TNF-α) and had no effect on weight gain of the rats.

CRP is synthesized in the liver and has been identified as an inflammatory marker. Increased CRP is associated with multiple risk factors for cardiovascular diseases, including obesity, insulin resistance, and hypertension, and has been demonstrated to have predictive value for risk of metabolic syndrome. Notably, during treatment with atypical antipsychotics, elevated CRP was associated with high BMI and high glucose levels in patients with psychotic disorders. There is good evidence that high CRP is associated with increasing serum levels of clozapine. For the first time the present study showed that clozapine administration for 6 weeks increased plasma levels of CRP in rats in the absence of IL-1β and TNF-α changes, suggesting that the increased levels of CRP in these clozapine-treated rats were not due to systemic inflammation. Considering the clozapine-induced hepatic steatosis and fibrosis along with increased ALT and AST, it is conceivable to link the high levels of CRP to liver dysfunction of the rats. In line with this correlation, patients with chronic liver failure had significantly higher CRP levels than others. Remarkably significant differences in CRP levels were still observed between these patients when analyses were restricted to noninfected patients. Therefore, the block of clozapine-induced CRP increase by artesunate suggests a protective action of this antimalarial on liver functions of the rats. Indeed, co-administration of artesunate and clozapine was shown to prevent rats from the clozapine-induced hepatic steatosis and cirrhosis along with increased plasma levels of triglycerides in the present study. These findings are in accordance with the results of a recent animal study in which artesunate decreased the plasma triglyceride while it attenuated liver steatosis and reduced the area of aortic root lesions in New Zealand rabbits fed a western-type diet developing hyperlipidemia. These protective effects have specific relevance to the prevention and treatment of the metabolic syndrome including liver dysfunctions seen in some of the schizophrenia patients after chronic administration of clozapine. These are also in line with the beneficial effects of artesunate on the multiple organ injury and dysfunction of rats submitted to hemorrhage shock.

We noticed an interesting phenomenon that both clozapine and artesunate had no effect on the body weight of rats during the 6-week experimental period, whereas significant differences existed between artesunate and clozapine + artesunate groups at weeks 5 and 6, to wit, the body weight of the latter was lower than that of the former. It seems that both artesunate and the double injection frequency and volume contributed to this difference in opposite directions. The former showed a tendency to increase the body weight of rats, whereas the latter seemed to decrease it. Future studies should avoid this limitation in experimental design. In addition, this study did not explore the underlying molecular mechanisms for the hypolipidemic effects and liver protection of artesunate in clozapine-treated rats. For this goal, in vitro experiments should be done in further studies. Last, future studies should figure out a safe and effective dose range for the add-on treatment of artesunate and clozapine in small animals, which would provide a meaningful reference for human studies.

In summary, intraperitoneal administration of clozapine for 6 weeks increased plasma levels of triglyceride and lead to hepatic steatosis and cirrhosis along with high levels of CRP, ALT, and AST in rats. But the treatment had no effect on weight gain and caused no hyperglycemia, hyperinsulinemia, and behavioral changes in the rats. These results are in line with most of the previous animal studies associating clozapine injection with hyperlipidemia rather than derangement of glucose metabolism and weight gain, whereas oral administration of clozapine was shown to result in hyperglycemia, hyperinsulinemia, and insulin resistance. These clozapine-induced changes were not seen in rats coadministered with clozapine plus artesunate. Together with recent animal studies showing hypolipidemic effects of artesunate in New Zealand White rabbits and rats and an in vitro study showing that artesunate inhibited adipogenesis in 3T3-L1 preadipocytes, the hypolipidemic effect of artesunate in clozapine-treated rats shown in the present study provided a significant impetus for psychiatrists to try add-on treatment of this antimalarial in schizophrenia patients with clozapine-induced metabolic adverse effects. If the metabolic side effects of clozapine are effectively blocked by artesunate in schizophrenia patients, the compliance of patients to clozapine will be greatly increased, and, thus, the therapeutic efficacy of it will be significantly improved.

Acknowledgments
This study was supported by a start-up fund from Shantou University Medical College and a postdoctoral research fellowship from Li Ka Shing Foundation.
Disclosure

The authors report no conflicts of interests in this work.

References


